Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Tardive dyskinesia Stories

2014-02-25 08:31:24

DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

2014-01-06 16:27:45

Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central...

2013-10-17 08:29:37

Seasoned Industry Veterans Driving Auspex's SD-809 Through Phase 3 Development for the Treatment of Chorea Associated with Huntington's Disease LA JOLLA, Calif., Oct. 17, 2013 /PRNewswire/ -- Auspex Pharmaceuticals, Inc., a privately-held clinical stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of orphan diseases, today announced the appointment of four life science industry veterans to the company's executive team: -- Pratik Shah, Ph.D.,...

2013-09-09 16:24:06

Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET / 2:00PM PT SAN DIEGO, Sept. 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant improvement. The pre-specified primary endpoint was the...

2013-07-01 16:26:33

Phase IIB Study Evaluating Twelve Weeks of Continuous Dosing With NBI-98854 SAN DIEGO, July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled...

2013-05-02 16:29:00

ELAGOLIX ENTERS PHASE IIB FOR UTERINE FIBROIDS, ENDOMETRIOSIS PHASE III PROGRAM ON TRACK SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2013. For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a net loss of $0.9 million, or $0.01 loss per share, for the same period in 2012. This $11.2 million change in operating...

2013-03-26 23:03:15

According to court documents, on March 7th, 2013 a Louisiana woman asked the US Supreme Court to hear her case alleging neurological damage from generic Reglan. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Reglan side effects. San Diego, CA (PRWEB) March 26, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently...

2013-02-06 12:26:05

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Swann Global Healthcare Conference 2013 in New York City. The live presentation takes place on Wednesday, February 13 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. If you...

2013-02-01 16:26:31

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, February 8, 2013 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Participants can...